Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
SNAP-89 residuesEEEMQRRADEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: SNAP-8, Acetyl Octapeptide-3, Acetyl Glutamyl Heptapeptide-1
Eight amino acids. That is all SNAP-8 (Acetyl Octapeptide-3) adds to the SNARE complex competition that Argireline started. Lipotec's own testing reported up to 63% wrinkle depth reduction over 28 days at 10% topical solution, with an average of 35% across subjects. Those numbers have not been independently replicated in any double-blind trial as of April 2026. The community figured this out quickly: consistent twice-daily use for 8 to 12 weeks yields subtle-to-moderate softening of crow's feet and forehead lines. Not Botox territory. But for a topical peptide you mix into a serum at home, the risk-to-reward ratio keeps DIY formulators coming back.
SNAP-8 (Acetyl Octapeptide-3, CAS 868844-74-0) is an eight-amino-acid synthetic peptide (sequence: Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2) that mimics the N-terminal domain of SNAP-25, one of three proteins in the SNARE complex. Lipotec, the company that invented it, reported up to 63% wrinkle reduction in their strongest responders. The average landed closer to 35% over 28 days of twice-daily application at 10% concentration. No independent double-blind RCT has confirmed either figure. SNAP-8 is the eight-residue extension of Argireline's six-amino-acid sequence. The SNARE complex handles vesicle docking at neuromuscular junctions. By competing for SNAP-25's binding position, SNAP-8 partially destabilizes vesicle fusion. Less acetylcholine gets released. Muscle contractions that create dynamic wrinkles lose some intensity. The result looks like a softer version of what Botox does, without needles and without paralysis. Real-world use centers on DIY skincare communities. The top protocol runs 10% Lotioncrafter SNAP-8 Solution C combined with 10% Argireline in a serum base, applied morning and evening. Community reports across 40 to 85 threads on r/DIYBeauty and r/SkincareAddiction describe subtle-to-moderate softening of expression lines after 8 to 12 weeks. Nobody claims Botox-level results. A 2020 review in Molecules [1] aggregated the available manufacturer data and confirmed the mechanism is scientifically sound. A JDD 2016 open-label trial (N=29) tested a multi-peptide formulation that included SNAP-8 and found statistically significant wrinkle improvement over 14 weeks, though SNAP-8's individual contribution could not be isolated. The biggest limitation is skin penetration. Less than 1% of SNAP-8 crosses the stratum corneum. Advanced delivery methods like microneedling or liposomal encapsulation can improve absorption, but add complexity. SNAP-8 is a research-only cosmeceutical ingredient with no FDA approval for any medical indication.
SNAP-8 targets the same molecular machinery that Botox does, but through competition rather than cleavage. The SNARE complex consists of three proteins: SNAP-25, syntaxin, and VAMP. Together they form a tight bundle that docks synaptic vesicles at the presynaptic membrane. When calcium floods in, this bundle triggers exocytosis of acetylcholine into the neuromuscular junction. Acetylcholine tells facial muscles to contract; repeated contraction creates expression lines. Botox cleaves SNAP-25 permanently (until new protein is synthesized). SNAP-8 takes a different approach. Its eight-amino-acid sequence mimics the N-terminal end of SNAP-25. It competes with endogenous SNAP-25 for its position in the SNARE trimer. This partial competition destabilizes vesicle fusion without blocking it entirely. In vitro data shows SNAP-8 inhibits glutamate release by up to 43% at 1.5 mM concentration (PMC7662462). Acetylcholine output drops. Muscle contraction intensity decreases. The practical difference: Botox paralyzes. SNAP-8 attenuates. Facial expressions remain functional. You get softening, not freezing. Dynamic wrinkles (forehead furrows, crow's feet, frown lines) lose some of their depth with repeated topical application. Static wrinkles, the ones visible even at rest, respond less because they involve structural collagen loss rather than muscular force. One constraint limits everything. SNAP-8 is a hydrophilic peptide trying to cross the lipophilic stratum corneum. Less than 1% reaches beyond the outermost skin layer based on available penetration data. Delivery systems (liposomes, multiple emulsions, cosmetic-depth microneedling) can improve this ratio, but standard serum application keeps effective concentrations low.
Mechanism (SNARE complex competition via SNAP-25 mimicry) is scientifically sound, but all headline efficacy figures originate from manufacturer Lipotec and have not been independently replicated in any double-blind RCT as of April 2026.
PMC7662462 (Cosmeceutical Peptides, Molecules 2020): aggregates Lipotec manufacturer data; JDD 2016 open-label trial (N=29, multi-peptide formulation incl. SNAP-8, 14 weeks) shows statistically significant wrinkle improvement but cannot isolate SNAP-8 contribution; Nguyen et al. Cosmetics 2024;11(4):118: most recent review, mechanism-focused, no new clinical data
No independent double-blind RCTs as of April 2026. Headline numbers (35% avg wrinkle reduction, 63% max, 30% more potent than Argireline, 43% in vitro glutamate inhibition) are all Lipotec-originated. Skin penetration <1% beyond stratum corneum limits dermal bioavailability. JDD trial cannot isolate SNAP-8 contribution from 6 other co-ingredients.
Subtle-to-moderate softening of dynamic expression lines with consistent 8–12 week twice-daily use. Results fall well short of Botox-level marketing claims. Well-tolerated and preferred by retinoid-intolerant users.
Science and community both confirm plausible mechanism and some anti-wrinkle activity. Divergence is on magnitude: manufacturer data claims 35–63% wrinkle depth reduction; community experience consistently reports subtle-to-moderate softening with no claims of Botox-equivalent results.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 100mcg | Daily |
| Moderate | 250mcg | Daily |
| Aggressive | 500mcg | Daily |
SNAP-8 is a topical peptide. There is no vial to reconstitute with bacteriostatic water. Instead, you are formulating a serum. The standard source material is Lotioncrafter SNAP-8 Solution C, which contains 0.05% active peptide. When you add this at 10% use rate into your serum base, your finished product contains 0.005% actual SNAP-8 peptide. At 5% use rate, you get 0.0025% active. At 3%, you get 0.0015% active. Most beginners start at 3 to 5% use rate and work up. The manufacturer's efficacy studies used 10% of their solution. Lotioncrafter sells the solution at $18.85 for 8g, $52.75 for 30g, or $83.95 for 60g. The thing most people miss: commercial SNAP-8 products that list the peptide near the bottom of their ingredient list contain negligible concentrations. You cannot judge dose adequacy from the front-of-label marketing claim. Ingredient list position is your only proxy without HPLC testing. Store your finished serum at 2 to 8 degrees Celsius in an airless pump bottle. Heat and UV break down peptide integrity faster than you would expect.
Apply twice daily for 12 weeks, then take a 2-week break. Wrinkle reduction is cumulative and peaks around week 4-8. Effects diminish gradually after stopping. No receptor desensitization has been reported, so extended continuous use is also practiced.
No receptor desensitization, antibody formation, or hormonal axis concern documented for topical SNAP-8. The 12 on/2 off cycle is a cosmeceutical convention providing a baseline assessment window, may reduce theoretical chronic contact sensitization risk, and mirrors clinical study duration (28-day protocols). Extended continuous use (no cycling) is also practiced without documented adverse outcomes.
Or use the universal Peptide Calculator for any peptide.
Expected: Subtle softening of fine expression lines; perceptible but not dramatic. Appropriate expectation-setter for first users.
Monitor: Check for contact sensitization in first 2 weeks. Patch test on inner arm if skin history of peptide sensitivity. No lab monitoring required.
SNAP-8 absorbs best on clean, dry skin without residual oils or moisturizer.
Apply a thin layer of your SNAP-8 serum (3 to 10% of Lotioncrafter Solution C in your formulation) to target areas. Focus on forehead furrows, crow's feet, and the glabellar frown lines between your eyebrows.
Wait 2 to 3 minutes for absorption before applying any other products. This absorption window matters for peptide uptake.
Apply your moisturizer, sunscreen, or next skincare layer after the wait period.
Twice-daily application matches the frequency used in manufacturer efficacy studies.
For the advanced protocol: layer Argireline serum (10%) over SNAP-8, followed by Matrixyl 3000 (8 to 10%). This covers both SNARE-mediated wrinkle relaxation and structural collagen support.
If combining with a derma roller for improved penetration, use cosmetic-depth needles only (0.25 to 0.5mm). Apply serum after rolling. Reduce your SNAP-8 concentration to 3 to 5% use rate when microneedling to lower irritation risk.
Store your serum at 2 to 8 degrees Celsius in an airless pump or dropper bottle away from light. Use within 3 months of preparation.
3–10% of 0.05% Lipotec solution = 0.0015–0.005% actual peptide in finished product
Apply to clean, dry skin twice daily. Allows 2–3 min before layering other products. Skin penetration <1% beyond stratum corneum per available data.
Same formulation concentration; enhanced transdermal delivery; effective dose at target tissue increased
Avoid on active acne, sensitized, or compromised skin. Use cosmetic-depth rollers only (≤0.5mm); deeper needling requires medical supervision. Reduce formulation to lower use rate (3–5%) when combining with needling to reduce irritation risk.
Same peptide dose; encapsulation theoretically improves dermal delivery
PMC11762834 (2025 peptide review) notes use of nanosphere delivery for SNAP-8 to improve penetration. Requires specialized formulation chemistry beyond standard serum-making.
Synergistic SNARE complex inhibition: combined use shows ~47% glutamate inhibition vs ~38% for Argireline alone (PMC7662462). Best-evidenced cosmeceutical peptide combination even if evidence is manufacturer-generated.
10% SNAP-8 Solution C + 10% Argireline solution in same serum base, twice daily
Complementary mechanism: SNAP-8 targets dynamic (muscle-driven) wrinkles via SNARE modulation; Matrixyl 3000 addresses structural aging through collagen stimulation (palmitoyl tripeptide-1 + tetrapeptide-7). Addresses different wrinkle types simultaneously.
Add Matrixyl 3000 at 8–10% use rate alongside SNAP-8 in same serum formulation
Complementary: GHK-Cu drives collagen/elastin synthesis, tissue repair, and gene-level skin remodeling while SNAP-8 relaxes expression muscle contraction. Popular in DIY community for a broad anti-aging approach.
Layer separately: SNAP-8 serum first, GHK-Cu serum after 2–3 min absorption; or use in separate AM/PM products
Complementary mechanism via opioid receptor modulation: works on different pathway than SNAP-8's SNARE inhibition. Combined use cited in PMC7662462; standard component of advanced neuromuscular stacks.
1% Leuphasyl + 10% SNAP-8 solution in same serum base
Same SNARE-pathway mechanism: additive facial muscle relaxation possible at combined doses; consult dermatologist before using both. Clinical risk at typical topical SNAP-8 concentrations is theoretical but unquantified.
Strong acid pH degrades peptide integrity; significant barrier disruption from high-strength exfoliants creates unpredictable absorption. Applies to peel-strength formulations; standard leave-on AHAs are not a significant concern with separated timing.
Pricing updated 2026-04-09
The most serious concern with SNAP-8 is not a side effect in the traditional sense. It is unrealistic expectations. The peptide cannot cause systemic harm at topical concentrations (less than 1% penetrates the stratum corneum), but users who expect Botox-level results from a serum they apply at home will be disappointed. That gap between marketing and reality is the primary source of negative community feedback. Contact sensitization is the only documented adverse reaction that warrants attention. It is rare but real. Some users develop localized redness, itching, or mild dermatitis after weeks of consistent application. In most reported cases, the sensitizer turned out to be a carrier ingredient or co-formulated active rather than SNAP-8 itself. If contact reactions appear, discontinue use and patch-test individual stack components separately to isolate the cause. Mild transient tingling immediately after application shows up in community reports. This typically relates to formulation pH rather than the peptide. A serum pH outside the 4.5 to 6.5 range can irritate skin independent of its active ingredients. If stinging persists, check your serum's pH before blaming the peptide. Temporary dryness at the application site is occasionally reported. It resolves with standard moisturizer application after the absorption window. There is one theoretical drug interaction worth flagging. If you also use botulinum toxin (Botox, Dysport), combining it with SNAP-8 could produce additive muscle relaxation effects through overlapping SNARE pathway mechanisms. The clinical risk at standard topical SNAP-8 concentrations is unquantified, but consult a dermatologist if you use both. Topical retinoids (tretinoin, adapalene) layered at the same time may increase skin sensitivity and irritation. The standard fix: apply SNAP-8 in the morning and retinol in the evening. Chemical exfoliants at peel-strength concentrations can degrade peptide integrity and disrupt the skin barrier unpredictably; standard leave-on AHAs and BHAs are fine with separated timing. No systemic side effects have been reported or would be expected from topical use given the penetration data. No human reproductive safety data exists. Pregnant or breastfeeding individuals should avoid use. Children under 18 lack safety data for this ingredient.
Verify SNAP-8 dosing and safety with a second opinion
Under-dosing in commercial products is the most common failure: SNAP-8 at high-quality concentration costs significantly more per unit volume, incentivizing brands to use it at cosmetic label concentrations rather than effective doses. Raw powder purity (CAS 868844-74-0) varies significantly across suppliers; no CIR-dedicated safety monograph exists specifically for acetyl octapeptide-3.
| Test | When | Target |
|---|---|---|
| Skin patch test | Before first application | — |
| Visual skin assessment | Weekly during first month | — |
Screen for contact sensitization to acetyl octapeptide-3 or excipients
Monitor for irritation, redness, or allergic contact dermatitis
No visible changes expected. SNAP-8 begins accumulating in the upper skin layers. Some users notice a mild tightening or smoothing sensation after application.
Early wrinkle softening may become apparent, especially on fine expression lines. Clinical studies show measurable wrinkle depth reduction beginning around week 2-3.
Peak reduction in wrinkle depth: clinical trials report average reductions of 35% with some subjects reaching 63% at the 28-day mark.
Continued maintenance of wrinkle reduction gains. Deeper expression lines may show further gradual improvement.
Effects are not permanent. Wrinkle depth gradually returns to baseline over 4-8 weeks after discontinuation.
Week 1: Nothing visible happens. SNAP-8 accumulates in the upper skin layers while SNARE complex competition starts at the molecular level. Some users feel a temporary smoothing or tightening right after application. That is the serum's humectant carrier, not the peptide working yet. Sensitive skin types occasionally report mild tingling or faint redness that resolves within minutes. Weeks 2 to 4: Early wrinkle softening becomes detectable for some users, particularly on fine expression lines around the crow's feet. Lipotec's manufacturer data shows measurable wrinkle depth reduction beginning around week 2 to 3 at twice-daily 10% application. Most community users report no perceptible change yet and are encouraged to continue through this window. Weeks 4 to 8: This is the peak reduction window. Manufacturer data puts average wrinkle depth reduction at 35%, with the strongest responders hitting 63% at 28 days. These are Lipotec-originated figures; no independent lab has replicated them. Community reports cluster here too. Moderate softening of expression lines is the consistent description. The effect is called "natural-looking" because facial expressions stay functional. Crow's feet and finer forehead lines respond best. Weeks 8 to 12: Maintenance phase. Gains from weeks 4 to 8 hold steady with continued twice-daily use. Deeper expression lines may show gradual further improvement. Most users evaluate at this point whether the results justify the cost and effort compared to alternatives like injectable Botox. After stopping: Effects are not permanent. SNAP-8 modulates SNARE function only while present in the skin. The effect is pharmacodynamic, not regenerative. Wrinkle depth returns toward baseline within 2 to 4 weeks of discontinuation. The community confirms this consistently. SNAP-8 is a maintenance ingredient, not a one-time treatment.
Peptide accumulates in upper skin layers; SNARE complex competition begins. No measurable structural change at this timepoint in any available study.
No visible change reported. Some users notice temporary smoothing or tightening immediately post-application: attributed to humectant carrier effects, not peptide action.
Manufacturer (Lipotec) data: measurable wrinkle depth reduction detectable from week 2–3 with twice-daily 10% application.
Some users report subtle softening around crow's feet. Most report no perceptible change yet; community encourages continuation.
Manufacturer data: 35% average wrinkle depth reduction; up to 63% in best-responders at 28-day mark. Note: these figures are Lipotec-originated and have not been independently replicated.
Positive reports cluster in this window. Moderate softening of expression lines. Effect described as 'natural-looking': facial expressions remain functional. Best results in crow's feet and finer forehead lines.
Continued maintenance of gains from weeks 4–8. Deeper expression lines may show gradual further improvement with continued twice-daily application.
Maintenance phase. Most users evaluate whether continued investment is worthwhile relative to alternatives. Some report sustained gains; others plateau without further improvement.
No persistent structural change: SNAP-8 modulates SNARE function only while present. Effect is pharmacodynamic, not regenerative.
Wrinkle depth returns to baseline within 2–4 weeks. Confirmed consistently across community as a maintenance-only ingredient.
Source: No systemic pharmacokinetic data available. SNAP-8 is a topical cosmeceutical peptide; skin penetration studies show less than 1% reaches beyond the stratum corneum.
Loading the interactive decay curve.
SNAP-8 (Acetyl Octapeptide-3) is classified as a cosmeceutical ingredient. It holds no FDA approval for any medical indication. It is not a drug, and no manufacturer may legally market it with claims to treat, cure, or prevent any disease or medical condition. The peptide is available through cosmeceutical ingredient suppliers (Lotioncrafter is the primary US distributor for Lipotec-licensed material) and in pre-formulated skincare products. No prescription is required for purchase or use. SNAP-8 is not listed as a controlled substance by the DEA. WADA status for athletes is not specifically addressed; however, topical cosmeceutical peptides without systemic bioactivity are generally outside WADA's scope. The content on this page is for informational and research purposes only. It does not constitute medical advice, and no provider-patient relationship is created by reading it. Consult a board-certified dermatologist before starting any new skincare regimen, particularly if you have pre-existing skin conditions or are using prescription topical medications.
Peptide Schedule Research TeamReviewed Apr 20267 Citations
